Nanoform Finland Oyj · OMXHEX:NANOFH
Nanoform Finland Oyj — Q1 2026 Earnings Presentation
33 slides from Nanoform Finland Oyj's earnings presentation, May 19, 2026
Slide 1: Nanoform – Q1 2026
Nanoform – Q1 2026 Conference call and webcast for investors and analysts May 19th, 2026
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” believe,” “est
Slide 3: Introduction and Business Highlights
Introduction Nanoform Breaker & Slide Option 2 Business Highlights CEO Edward Hæggström Nanoform.com | @nanoform 3
Slide 4: Introduction to Nanoform
Introduction to Nanoform NANOFORM NANOFORM MIDTERM REVENUES TO NANOFORM OFFERING CUSTOMERS TECHNOLOGIES BUSINESS TARGETS NANOFORM BREAK THE WALL 2030 Small molecules Service fees 3 nanoformed medicines Global pharma launched by 2030 Development and Biologics Small molecules commercial milestones Mid
Slide 5: Business highlights
Business highlights I Record first quarter revenue (+45%) and gross margin (94%) - operating costs fell by 31% First exculsivity deal signed around our Biologics technology, with US Nasdaq listed II biopharmceutical company Nanoenzalutamide project continues with multitrack strategy supported by all
Slide 6: Financials and Guidance
Financials Nanoform Breaker Slide & Option 2 Guidance CFO Albert Hæggström Nanoform.com | @nanoform 6
Slide 7: Nr of projects signed - quarterly and trailing 12 months
Nr of projects signed - quarterly and trailing 12 months Nanoform.com | @nanoform 7 7
Slide 8: Income (revenue + other operating income) – quarterly and trailing 12 months
Income (revenue + other operating income) – quarterly and trailing 12 months Nanoform.com | @nanoform 8 8
Slide 9: Record first quarter revenue, income and gross margin
Record first quarter revenue, income and gross margin Nanoform.com | @nanoform 9 9
Slide 10: Significantly lower operating expenses led to improved EBITDA
Significantly lower operating expenses led to improved EBITDA – effect from personnel reductions small in 1Q, will grow in 2Q, and full effect in 3Q Nanoform.com | @nanoform 10 10
Slide 11: Underlying EBITDA improving – annualized trailing 12 months
Underlying EBITDA (ex options & associated companies) improving – annualized trailing 12 months already less than EUR 10m negative Nanoform.com | @nanoform 11 11
Slide 12: Nanoform near-term business targets 2026
Nanoform near-term business targets 2026 I Cash burn below EUR 10m II First marketing authorization application for a nanoformed medicine submitted III Increased number of non-GMP and GMP projects signed in 2026 To sign development and license/commercial supply agreements on several IV product kerne
Slide 13: Nanoform midterm business targets 2030
Nanoform midterm business targets 2030 3 Income* nanoformed growth EBIT margin medicines > 50% CAGR > 30% by 2030 launched 2026-2030 by 2030 * Revenue + other operating income (milestones, fees, royalties, profit shares etc.) Nanoform.com | @nanoform 13
Slide 14: Nanoform mid-term annual income potential by 2030
Nanoform mid-term annual income potential by 2030 Exclusivity fees & royalties & profit share: > EUR 50m Commercial milestones, small molecules: > EUR 25m Commercial GMP supply, small molecules: > EUR 10m Development milestones, Biologics: > EUR 10m Development milestones, small molecules: > EUR 10m
Slide 15: Commercial
Commercial Nanoform Breaker Slide Option 2 CCO Christian Jones & CDO Peter Hänninen Nanoform.com | @nanoform 15
Slide 16: Commercial overview
Commercial overview I Commercialization of our technologies for small molecules and biologics is in full speed II Developing our Product Kernels with partners and taking the three leading assets to market by 2030 III Executing innovator pharma customer projects and signing new customer projects IV G
Slide 17: Nanoenzalutamide project continues with multitrack strategy
Nanoenzalutamide project continues with multitrack strategy - supported by all parties involved Multitrack strategy: Evaluating selected national submissions in European markets that may accept the current ∙ data package ∙ Advancing further formulation work to also meet the remaining Cmax requiremen
Slide 18: Nanoform signs first Biologics technology exclusivity agreement
Nanoform signs first Biologics technology exclusivity agreement ▪ Exclusivity agreement for ultra-high concentration subcutaneous delivery ▪ With a U.S. Nasdaq listed biopharmaceutical company ▪ Partner pays Nanoform a non-refundable initial $1m fee to secure exclusivity for one clinically and comme
Slide 19: Nanoform Product Kernel overview
Nanoform Product Kernel overview* Nanoform at Nanoform Product Kernels Nanoform Pre-Clinical (non-GMP) Nanoform Clinical (GMP) Market Expected Nanoform Development Targeted Pre- Dosage form PoP* / Delivery route First cGMP Phase 1 / Pilot Pivotal - final - First Dossier Earliest possible Originator
Slide 20: Future of Biologics delivery & formulation
Future of Biologics delivery & formulation ▪ Subcutaneous ▪ Suspension ▪ Particle properties delivery will become formulations enable are critical for the dominant high drug suspension standard (>50%) for concentrations → performance → new and marketed lower injection Nanoform’s biologics volumes, m
Slide 21: Exclusivity market for subQ delivery – as of 12/2025
Exclusivity market for subQ delivery – as of 12/2025 Target Receptor Acumen Alexion/AZ Amgen Argenx BMS Lilly JnJ Merck Novartis Regeneron Roche Takeda ViiV OTHERS Amyloid A4 protein Halozyme 4 C2 Halozyme 1 C5 Halozyme 10 CD20 Halozyme 8 CD38 Halozyme 12 EGFRxMET Halozyme 7 Halozyme& FcRn Elektrofi
Slide 22: Established exclusivity market for subQ, only a handful of technology providers
Established exclusivity market for subQ, dozens of large companies targeting 100s of receptors, only a handful of technology providers, 05/26 Alexion Daiichi Regenero Un Target Receptor Acumen Argenx Biogen BMS GSK Lilly JnJ Merck Merus Novartis Oruka Pfizer Roche Sandoz Skye Takeda ViiV
Slide 23: Q & A
Q&A www.nanoform.com 23 San Diego - Chicago - New York - Lisbon - London - Cambridge - Bordeaux - Cologne - Stockholm - Helsinki - Tokyo | @nanoform Nanoform.com
Slide 24: Appendix
Nanoform Breaker Slide Q & A2 Option APPENDIX www.nanoform.com San Diego - New York - Lisbon - Oxford – London - Cambridge - Bordeaux - Stockholm – Budapest - Helsinki 24 Nanoform.com | @nanoform
Slide 25: Small Molecules - Proprietary technology
Small Molecules - Proprietary technology Green technology Controlled Expansion of Supercritical Solutions - CESS® Contro lled ➢ Relatively simple process developed through combining deep knowledge in physics, chemistry, and pharma The CESS® technology platform was described in detail in the IPO pros
Slide 26: Large molecules - Proprietary technology
Large molecules - Proprietary technology Green technology Nanoforming process for biologics API = active pharmaceutical ingredient Nebulization = turns liquid into mist Ionization = particles electrically charged Nanoform.com | @nanoform 26
Slide 27: Nanoform technology is proven with in-vitro, in-vivo, and clinical study results
Nanoform technology is proven with in-vitro, in-vivo, and clinical study results and experience with 100 unique molecules Oncology: Biologics: Hydrogels: Replaced ASD formulations with nanocrystalline high drug load Demonstrated, in partnership Shown high drug load formulations for Enza/Apalutamide.
Slide 28: Nanoform technologies supercharge performance of a wide variety of molecules
Nanoform technologies supercharges performance of a wide variety of molecules, products and indications Higher Dose Load Improved Superior Alternative Enhancement for Superior for Oral drugs, mAbs Bioavailability to ASD Challenging Target Reformulations Peptides and Proteins Formulations Product Pro
Slide 29: Nanoform Product Kernels
Nanoform Product Kernels Nanoform internal Development partners Commercial partners Product Kernel work Originator Originator 1. Value proposition around a medicine or or candidate, called ‘Product Kernel’ Supergeneric / High value medicine Supergeneric / High value medicine company company 1. Upfro
Slide 30: Attractive revenue model with pharma and biotech customers
Attractive revenue model with pharma and biotech customers Proof of Concept / Phase Phase I – III clinical trials Drugs on the market Proof of Process Certification Non-GMP GMP GMP • Proof of concept study - assessment of • API for clinical trials are manufactured in • Drugs that have passed the tri
Slide 31: Management team: Multi-disciplinary with international merits
Management team: Multi-disciplinary with international merits CEO & Co-founder; Ph.D. (Applied physics), MBA CFO and member of the Board; B.Sc. (Economics) Edward Hæggström • Professor at the University of Helsinki, Head of Electronics Research Lab. Albert Hæggström • 20 years of finance and investi
Slide 32: Board of directors: Top executives from leading industry positions
Board of directors: Top executives from leading industry positions Miguel Calado Albert Hæggström Chairman of the Board CFO and Board Member • Previously CFO at international particle engineering CDMO • 20 years of finance and investing experience company Hovione Group • Prior roles include position
Slide 33: Contact details
CEO Edward Hæggström edward.haeggstrom@nanoform.com +358 50 317 54 93 CFO Albert Hæggström albert.haeggstrom@nanoform.com +358 40 161 4191 DIR Henri von Haartman hvh@nanoform.com +46 76866 50 11 Nanoform.com | @nanoform